Clinical trials
Generalized Myasthenia Gravis clinical trials
Below are recruiting generalized myasthenia gravis clinical trials, each written for real people, not researchers. We’re tracking 59 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07039916RecruitingPhase 3
Study of IMVT-1402 for mild to severe generalized myasthenia gravis
This trial tests an investigational drug called IMVT-1402 to see if it improves symptoms in people with generalized myasthenia gravis (gMG). If you have mild to severe gMG and are looking for new treatment options, this study may be a fit.
Huntsville, AlabamaAges 18–80 - NCT06987539RecruitingPhase 2
Inebilizumab for children with generalized myasthenia gravis
This study tests a new drug called inebilizumab for children with generalized myasthenia gravis (gMG), a condition causing muscle weakness. The drug aims to reduce the immune system's attack on nerves, which may improve symptoms. The study will check how safe and effective it is for young patients.
Philadelphia, PennsylvaniaAges 2–17 - NCT06967480Recruiting
Early ravulizumab for recent-onset generalized myasthenia gravis
This trial tests an early treatment with ravulizumab (a medication that blocks part of the immune system) for people who have recently developed moderate-to-severe generalized myasthenia gravis. The goal is to see if starting treatment early can improve symptoms and daily life.
BergamoAges 18 years+ - NCT06909214RecruitingPhase 4
Study of efgartigimod for new-onset generalized myasthenia gravis
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
La Jolla, CaliforniaAges 18 years+ - NCT06909253Recruiting
Study of ravulizumab for generalized myasthenia gravis
This study looks at how well ravulizumab works for people with generalized myasthenia gravis (gMG) who have not tried complement inhibitors before. The goal is to see if this treatment helps improve symptoms in everyday life.
BydgoszczAges 18 years+ - NCT06860633RecruitingPhase 4
Efgartigimod for worsening myasthenia gravis in hospital
This trial tests a drug called efgartigimod for people with myasthenia gravis who are in the hospital because their symptoms are getting worse. The goal is to see if it can help them recover faster and avoid needing a breathing tube.
Aurora, ColoradoAges 18 years+ - NCT06688435RecruitingPhase 1
Immune cell therapy for hard-to-treat myasthenia gravis
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
JinanAges 18–65 - NCT06607627RecruitingPhase 3
Testing gefurulimab in children with generalized myasthenia gravis
This study tests a new drug called gefurulimab in children and teens with generalized myasthenia gravis (a disease that causes muscle weakness). It looks at how safe and effective the drug is, and how it works in the body.
Washington D.C., District of ColumbiaAges 6–17 - NCT06491238Recruiting
Light vs. moderate exercise for myasthenia gravis
This study compares light exercise (like gentle walking) to moderate exercise (like brisk walking) for people with myasthenia gravis. It aims to see if one type of exercise is safer and more helpful for managing symptoms.
Saint Paul, MinnesotaAges 18–80 - NCT06463587RecruitingPhase 3
Oral cladribine for generalized myasthenia gravis
This study tests a new oral medication (cladribine) to see if it can reduce muscle weakness and daily symptoms in people with generalized myasthenia gravis. It compares the drug to a placebo (a pill with no active medicine) to check safety and effectiveness.
Phoenix, ArizonaAges 18 years+ - NCT06447597RecruitingPhase 2/Phase 3
Study of B007 for Generalized Myasthenia Gravis
This trial tests a new drug called B007 for people with generalized myasthenia gravis who have specific antibodies and moderate to severe muscle weakness. It aims to see if the drug can improve daily activities and reduce symptoms.
BeijingAges 18–70 - NCT06371040RecruitingPhase 1
CAR-T cell therapy for severe myasthenia gravis
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
Xi'an, ShaanxiAges 18–80 - NCT06435312Enrolling by invitationPhase 3
Studying zilucoplan for children with generalized myasthenia gravis
This study gives an injectable medicine called zilucoplan to children who were part of an earlier trial and could benefit from more treatment. It aims to see if zilucoplan is safe and helpful for young patients with generalized myasthenia gravis.
MilanAges 12 years+ - NCT06392386RecruitingPhase 2/Phase 3
Efgartigimod for children with generalized myasthenia gravis
This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.
Charlotte, North CarolinaAges 2–17 - NCT06359041RecruitingPhase 1/Phase 2
CABA-201 cell therapy for generalized myasthenia gravis
This trial tests a new cell therapy called CABA-201 for people with generalized myasthenia gravis. It aims to reset the immune system to reduce muscle weakness and improve daily functioning.
Orange, CaliforniaAges 18–70 - NCT06193889RecruitingPhase 2/Phase 3
Car-t cell therapy for generalized myasthenia gravis
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
Los Angeles, CaliforniaAges 18–75 - NCT06055959RecruitingPhase 2/Phase 3
Zilucoplan for children with generalized myasthenia gravis
This study tests a new daily shot (zilucoplan) for children and teens with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. It aims to see if the drug is safe and helps improve strength and daily functioning.
Chicago, IllinoisAges 12–17 - NCT05374590Enrolling by invitationPhase 2/Phase 3
Long-term safety study of efgartigimod for young myasthenia gravis patients
This trial checks the long-term safety of efgartigimod given through an IV and as a quick under-the-skin injection in children with generalized myasthenia gravis (gMG). It may help your care team understand how safely this treatment can be used over time for kids who already took related study treatments.
Chicago, IllinoisAges 2–18 - NCT05265273RecruitingPhase 2/Phase 3
Nipocalimab for children with generalized myasthenia gravis
This trial studies nipocalimab, an immune-focused medicine, to see if it can improve generalized myasthenia gravis (gMG) in children ages 2 to under 18. It may help reduce weakness caused by this autoimmune muscle disease, but you must meet specific antibody and health requirements.
Phoenix, ArizonaAges 2–17 - NCT04951622RecruitingPhase 3
Testing nipocalimab for adults with generalized myasthenia gravis
This Phase 3 study tests nipocalimab, a medication given by infusion (and in some groups by injections under the skin), to improve symptoms in adults with generalized myasthenia gravis (MG). It may help reduce weakness in daily activities, especially if you meet specific symptom and safety criteria.
Paradise Valley, ArizonaAges 18 years+ - NCT04806620Recruiting
Online app study for brain inflammation lifestyle data
This study uses a digital platform (app/website) to collect lifestyle and symptom information to better understand brain inflammation. You may qualify if you have certain conditions like Long COVID, migraines, autoimmune disease, inflammatory gut issues, mood disorders, or if you are a healthy comparison person.
Delafield, WisconsinAges 2 years+ - NCT04833894RecruitingPhase 2/Phase 3
Efgartigimod for children with generalized myasthenia gravis
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
Chicago, IllinoisAges 2–18 - NCT04202341Recruiting
Registry for people with generalized myasthenia gravis on Alexion treatment
This study is a registry, meaning it collects health and disease information from people with generalized myasthenia gravis (gMG) who are receiving Alexion C5 “inhibition” therapies. Your data can help researchers better understand real-world outcomes and disease patterns over time.
Birmingham, AlabamaAges 18 years+ - NCT07413835Recruiting
Study of HN2302 for hard-to-treat myasthenia gravis
This trial tests a new medicine called HN2302 for people with generalized myasthenia gravis (MG) that hasn't improved with standard treatments. It aims to see if HN2302 is safe and helps reduce muscle weakness symptoms.
Xuzhou, JiangsuAges 18–80
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for generalized myasthenia gravis?
- Yes. Clin2 currently lists 59 recruiting generalized myasthenia gravis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a generalized myasthenia gravis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a generalized myasthenia gravis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.